{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:50:11Z","timestamp":1784850611152,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiolog\u00eda"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.rx.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T19:32:22Z","timestamp":1509132742000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retenci\u00f3n de compuestos de gadolinio usados en resonancia magn\u00e9tica: revisi\u00f3n cr\u00edtica y recomendaciones de las agencias regulatorias"],"prefix":"10.1016","volume":"59","author":[{"given":"L.","family":"Mart\u00ed-Bonmat\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mart\u00ed-Bonmat\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rx.2017.09.007_bib0325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00330-012-2597-9","article-title":"Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines","volume":"23","author":"Thomsen","year":"2013","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0330","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13244-015-0420-2","article-title":"Revisiting the risks of MRI with gadolinium based contrast agents \u2014 review of literature and guidelines","volume":"6","author":"Khawaja","year":"2015","journal-title":"Insights Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0335","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). (Consultado en julio de 2017.) Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2017\/NI-MUH_FV_07-gadolinio.htm."},{"key":"10.1016\/j.rx.2017.09.007_bib0340","unstructured":"European Medicines Agency. Reviewing gadolinium contrast agents used in MRI scans. (Consultado en marzo de 2017.) Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/gadolinium_contrast_agents_31\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500223161.pdf."},{"key":"10.1016\/j.rx.2017.09.007_bib0345","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jmri.21969","article-title":"Biodistribution of gadolinium-based contrast agents, including gadolinium deposition","volume":"30","author":"Aime","year":"2009","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","article-title":"Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review","volume":"21","author":"Port","year":"2008","journal-title":"Biometals."},{"key":"10.1016\/j.rx.2017.09.007_bib0355","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jmri.21966","article-title":"Primer on gadolinium chemistry","volume":"30","author":"Sherry","year":"2009","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0360","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jmri.21967","article-title":"Role of thermodynamic and kinetic parameters in gadolinium chelate stability","volume":"30","author":"Id\u00e9e","year":"2009","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0365","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2015142690","article-title":"Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy","volume":"276","author":"Kanda","year":"2015","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0370","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","article-title":"Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion","volume":"51","author":"Lancelot","year":"2016","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0375","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","article-title":"Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function","volume":"51","author":"Murata","year":"2016","journal-title":"Investig Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0380","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.mri.2016.09.003","article-title":"Gadolinium deposition: is it chelated or dissociated gadolinium?","volume":"34","author":"Tweedle","year":"2016","journal-title":"How can we tell?. Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0385","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/RLI.0000000000000327","article-title":"Intrathecal contrast-enhanced magnetic resonance imaging-related brain signal changes: residual gadolinium deposition?","volume":"52","author":"\u00d6ner","year":"2017","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0390","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00330-016-4654-2","article-title":"Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue","volume":"27","author":"Jost","year":"2017","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0395","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The glymphatic system: a beginner's guide","volume":"40","author":"Jessen","year":"2015","journal-title":"Neurochem Res."},{"key":"10.1016\/j.rx.2017.09.007_bib0400","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejrad.2008.01.026","article-title":"Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis","volume":"66","author":"Abraham","year":"2008","journal-title":"Eur J Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0405","first-page":"58","article-title":"2015 Update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR","volume":"17","author":"Bruder","year":"2015","journal-title":"Large multi-national and multi-ethnical population experience with 37788 patients from the EUROCMR registry. J Cardiovasc Magn Reson."},{"key":"10.1016\/j.rx.2017.09.007_bib0410","doi-asserted-by":"crossref","first-page":"W138","DOI":"10.2214\/AJR.10.4885","article-title":"Incidence of immediate gadolinium contrast media reactions","volume":"196","author":"Prince","year":"2011","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.rx.2017.09.007_bib0415","doi-asserted-by":"crossref","first-page":"e3170","DOI":"10.1097\/MD.0000000000003170","article-title":"The incidence, classification, and management of acute adverse reactions to the low-osmolar iodinated contrast media Isovue and Ultravist in contrast-enhanced computed tomography scanning","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Balt)."},{"key":"10.1016\/j.rx.2017.09.007_bib0420","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2016.12126","article-title":"Association between MRI exposure during pregnancy and fetal and childhood outcomes","volume":"316","author":"Ray","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.rx.2017.09.007_bib0425","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jmri.25486","article-title":"Observational study on the safety profile of gadoterate meglumine in 35,499 patients: the SECURE study","volume":"45","author":"Soyer","year":"2017","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0430","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium \u2212 a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rx.2017.09.007_bib0435","doi-asserted-by":"crossref","first-page":"e0129720","DOI":"10.1371\/journal.pone.0129720","article-title":"An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.rx.2017.09.007_bib0440","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","article-title":"Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions","volume":"18","author":"Sieber","year":"2008","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0445","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1055\/s-0033-1356403","article-title":"Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis","volume":"186","author":"Heverhagen","year":"2014","journal-title":"Rofo."},{"key":"10.1016\/j.rx.2017.09.007_bib0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/RMR.0b013e3182a14e79","article-title":"Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis","volume":"24","author":"Haneder","year":"2015","journal-title":"Top Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0455","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00166.2016","article-title":"Pathophysiology of gadolinium-associated systemic fibrosis","volume":"311","author":"Wagner","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0460","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-063014-124936","volume":"67","author":"Todd","year":"2016","journal-title":"Annu Rev Med."},{"key":"10.1016\/j.rx.2017.09.007_bib0465","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jmri.21980","article-title":"Mechanism of NSF: new evidence challenging the prevailing theory","volume":"30","author":"Newton","year":"2009","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0470","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cei.12211","article-title":"Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents","volume":"175","author":"Wermuth","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.rx.2017.09.007_bib0475","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiol.10091131","article-title":"Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation","volume":"256","author":"Edward","year":"2010","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0480","unstructured":"American College of Radiology. Nephrogenic systemic fibrosis. ACR Manual on Contrast Media \u2013 Version 10.2; 2016."},{"key":"10.1016\/j.rx.2017.09.007_bib0485","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/radiol.11102340","article-title":"Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines","volume":"260","author":"Wang","year":"2011","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0490","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/RLI.0000000000000259","article-title":"Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide","volume":"51","author":"Bruce","year":"2016","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0495","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","author":"Kanda","year":"2014","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0500","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1148\/radiol.2016152864","article-title":"Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents","volume":"282","author":"Zhang","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1148\/radiol.2016160356","article-title":"Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR Imaging","volume":"282","author":"Flood","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0510","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RLI.0000000000000374","volume":"52","author":"Runge","year":"2017","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0515","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.2016162535","article-title":"Is there long-term signal intensity increase in the central nervous system on T1-weighted images after MR imaging with the hepatospecific contrast agent gadoxetic acid?. A cross-sectional study in 91 patients","volume":"282","author":"Kahn","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0520","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.2016162241","article-title":"No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents","volume":"282","author":"Radbruch","year":"2017","journal-title":"Radiology."},{"issue":"Suppl 1","key":"10.1016\/j.rx.2017.09.007_bib0525","first-page":"1","article-title":"Evaluation of gadolinium brain deposits in melanoma patients: a retrospective study","volume":"8","author":"Moreno Negrete","year":"2017","journal-title":"Insights Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0530","doi-asserted-by":"crossref","DOI":"10.1007\/s00247-017-3874-1","article-title":"Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children","author":"Rossi Espagnet","year":"2017","journal-title":"Pediatr Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0535","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3174\/ajnr.A5270","article-title":"T1 Signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease","volume":"38","author":"Schneider","year":"2017","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0540","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2017161151","article-title":"Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study","volume":"285","author":"Tibussek","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0545","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1148\/radiol.2017162980","article-title":"Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent","volume":"283","author":"Radbruch","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0550","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0555","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/RLI.0000000000000352","article-title":"Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats","volume":"52","author":"Frenzel","year":"2017","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0560","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1148\/radiol.2016152846","article-title":"Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients","volume":"281","author":"Maximova","year":"2016","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0565","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/RLI.0000000000000241","article-title":"Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats","volume":"51","author":"Robert","year":"2016","journal-title":"Investig Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0570","first-page":"161594","article-title":"Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates","author":"McDonald","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0575","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","article-title":"Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy","volume":"41","author":"White","year":"2006","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0580","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1039\/b905145g","article-title":"Incorporation of excess gadolinium into human bone from medical contrast agents","volume":"1","author":"Darrah","year":"2009","journal-title":"Metallomics."},{"key":"10.1016\/j.rx.2017.09.007_bib0585","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/ndt\/gfr085","article-title":"Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis \u2212 an autopsy-based review","volume":"26","author":"Sanyal","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rx.2017.09.007_bib0590","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1148\/radiol.2016160905","article-title":"Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study","volume":"282","author":"Smith","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0595","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00330-010-1805-8","article-title":"High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review","volume":"20","author":"Giesel","year":"2010","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0600","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00330-015-3900-3","article-title":"ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents","volume":"26","author":"Neri","year":"2016","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0605","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.mri.2016.09.005","article-title":"Gadolinium toxicity and treatment","volume":"34","author":"Ramalho","year":"2016","journal-title":"Magn Reson Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0610","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cmmi.88","article-title":"Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as \u2018sponges\u2019 of Gd3+ ions","volume":"1","author":"Cabella","year":"2006","journal-title":"Contrast Media Mol Imaging."},{"key":"10.1016\/j.rx.2017.09.007_bib0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0720-048X(95)00679-K","article-title":"Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging","volume":"21","author":"Vogler","year":"1995","journal-title":"Eur J Radiol."},{"key":"10.1016\/j.rx.2017.09.007_bib0620","doi-asserted-by":"crossref","first-page":"e0171704","DOI":"10.1371\/journal.pone.0171704","article-title":"The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity \u2212 a systematic review","volume":"12","author":"Olchowy","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.rx.2017.09.007_bib0625","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jama.2016.8096","article-title":"Association between gadolinium contrast exposure and the risk of Parkinsonism","volume":"316","author":"Welk","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.rx.2017.09.007_bib0630","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1148\/radiol.2016161626","article-title":"Gadolinium retention in the body and brain: is it time for an international joint research effort?","volume":"282","author":"Quattrocchi","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.rx.2017.09.007_bib0635","unstructured":"European Medicines Agency (EMA). Gadolinium-containing contrast agents. (Consultado en Abr de 2017.) Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Gadolinium-containing_contrast_agents\/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f."},{"key":"10.1016\/j.rx.2017.09.007_bib0640","unstructured":"American College of Radiology. ACR response to the European PRAC recommendations. (Consultado en abril de 2017.) Disponible en: https:\/\/www.acr.org\/About-Us\/Media-Center\/Press-Releases\/2017-Press-Releases\/20170404-ACR-Response-to-the-European-PRAC-Recommendations."}],"container-title":["Radiolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033833817301522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033833817301522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T08:21:09Z","timestamp":1535271669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033833817301522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0033833817301522"],"URL":"https:\/\/doi.org\/10.1016\/j.rx.2017.09.007","relation":{},"ISSN":["0033-8338"],"issn-type":[{"value":"0033-8338","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retenci\u00f3n de compuestos de gadolinio usados en resonancia magn\u00e9tica: revisi\u00f3n cr\u00edtica y recomendaciones de las agencias regulatorias","name":"articletitle","label":"Article Title"},{"value":"Radiolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rx.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SERAM. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}